METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR SIMULTANEOUS ESTIMATION OF GLIMEPIRIDE AND ROSIGLITAZONE IN BULK AND TABLET DOSAGE FORM

Dr.B. Madhu Harika; Prof Y. Rajendra Prasad

Volume : VIII, Issue : I, January - 2019

METHOD DEVELOPMENT AND VALIDATION BY RP-HPLC FOR SIMULTANEOUS ESTIMATION OF GLIMEPIRIDE AND ROSIGLITAZONE IN BULK AND TABLET DOSAGE FORM

Dr. B. Madhu Harika, Prof Y. Rajendra Prasad

Abstract :

The proposed study, a new method development and validation by RP-HPLC has been developed for estimation of Glimepiride and Rosiglitazone in bulk and tablet dosage form. The present method was a sensitive, precise and accurate RP-HPLC method. To optimize the mobile phase, various combinations of buffer and organic solvents were used on Inertsil ODS-150x4.6mm, 5� column. Altima-150x4.6mm, 5� Then the mobile phase containing a mixture of phosphate buffer (pH 4.0) and Acetonitrile 60:40 %v/v were selected at a flow rate of 1ml/min for developing the peaks with good shape and resolution was found resulting in short retention time, baseline stability and minimum noise. Retention times of Glimepiride and Rosiglitazone were found to be 2.109min and 4.657min respectively. Quantitative linearity obeyed in the concentration range of 10-60 �g/ml and 20-120 �g/ml of Glimepiride and Rosiglitazone respectively. The limit of detection and limit of quantification were found to be 0.002 �g/ml and 0.06 �g/ml (Glimepiride) and 0.23 �g/ml and 0.70 �g/ml (Rosiglitazone) respectively, which indicates the sensitivity of the method. The high percentage recovery indicates that the proposed method is highly accurate. No interfering peaks were found indicating the excipients used in formulations didn�t interfere with the estimation of the drugs.